Evonik Q3 core profit broadly in-line on increased demand, higher pricing

This post was originally published on this site

The company, which makes ingredients for products ranging from animal feed and diapers to ingredients for Pfizer/BioNTech’s COVID-19 vaccine, reported adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA) of 645 million euros ($747.23 million) in the third quarter, up 24% and slightly above analysts’ forecast of 641.1 million euros in a company-provided poll.

($1 = 0.8632 euros)